Literature DB >> 21956288

Platelet decline as a predictor of brain injury in HIV infection.

Ann B Ragin1, Gypsyamber D'Souza, Sandra Reynolds, Eric Miller, Ned Sacktor, Ola A Selnes, Eileen Martin, Barbara R Visscher, James T Becker.   

Abstract

An association between platelet decline and increased risk of progression to dementia has been observed in an advanced HIV infection cohort study. This investigation evaluated the prognostic significance of platelet decline for dementia, for psychomotor slowing, and for brain injury, as quantified in vivo, in a much larger population of HIV+ men. Platelet counts and neurocognitive data were available from biannual visits of 2,125 HIV+ men participating in the prospective, Multicenter AIDS Cohort Study from 1984 to 2009. Brain volumetric data were also available from an imaging substudy of 83 seropositive participants aged 50 and older. The association of platelet counts with neurocognitive outcome was assessed using Cox proportional hazard models where change in platelet count from baseline was a time-updated variable. Marked platelet decline was associated with increased risk of dementia in univariate analysis (hazard ratio [HR] = 2.5, 95% confidence interval [CI] = 1.8-3.5), but not after adjustment for CD4 cell count, HIV viral load, age, study site, hemoglobin, race, education, smoking, and alcohol use (HR = 1.4, 95% CI = 0.78-2.5). Platelet decline did not predict psychomotor slowing in either univariate (HR = 0.79, 95% CI = 0.58-1.08) or multivariate (HR = 1.10, 95% CI = 0.73-1.67) analysis. Analysis of brain volumetric data, however, indicated a relationship between platelet decline and reduced gray matter volume fraction in univariate (p = 0.06) and multivariate (p < 0.05) analyses. Platelet decline was not an independent predictor of dementia or psychomotor slowing, after adjusting for stage of disease. Findings from a structural brain imaging substudy of older participants, however, support a possible relationship between platelet decline and reduced gray matter.

Entities:  

Mesh:

Year:  2011        PMID: 21956288      PMCID: PMC3472427          DOI: 10.1007/s13365-011-0053-2

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  44 in total

Review 1.  The CD40/CD154 receptor/ligand dyad.

Authors:  U Schönbeck; P Libby
Journal:  Cell Mol Life Sci       Date:  2001-01       Impact factor: 9.261

2.  Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.

Authors:  M Depairon; S Chessex; P Sudre; N Rodondi; N Doser; J P Chave; W Riesen; P Nicod; R Darioli; A Telenti; V Mooser
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

3.  Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis.

Authors:  M Gawaz; K Brand; T Dickfeld; G Pogatsa-Murray; S Page; C Bogner; W Koch; A Schömig; F Neumann
Journal:  Atherosclerosis       Date:  2000-01       Impact factor: 5.162

4.  Beta amyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients.

Authors:  M Nebuloni; A Pellegrinelli; A Ferri; S Bonetto; R Boldorini; L Vago; M P Grassi; G Costanzi
Journal:  AIDS       Date:  2001-03-30       Impact factor: 4.177

Review 5.  CD40 signaling and plaque instability.

Authors:  U Schönbeck; P Libby
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

6.  Erythropoietin therapy for acute stroke is both safe and beneficial.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

7.  Factors affecting brain structure in men with HIV disease in the post-HAART era.

Authors:  James T Becker; Victoria Maruca; Lawrence A Kingsley; Joanne M Sanders; Jeffery R Alger; Peter B Barker; Karl Goodkin; Eileen Martin; Eric N Miller; Ann Ragin; Ned Sacktor; Ola Selnes
Journal:  Neuroradiology       Date:  2011-03-22       Impact factor: 2.804

Review 8.  The emerging role of CD40 ligand in HIV infection.

Authors:  R S Kornbluth
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

Review 9.  Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice?

Authors:  F Boehlen; K J Clemetson
Journal:  Transfus Med       Date:  2001-12       Impact factor: 2.019

Review 10.  Role of blood platelets in infection and inflammation.

Authors:  Matthias H F Klinger; Wolfgang Jelkmann
Journal:  J Interferon Cytokine Res       Date:  2002-09       Impact factor: 2.607

View more
  12 in total

1.  Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1.

Authors:  Meera V Singh; Donna C Davidson; Michelle Kiebala; Sanjay B Maggirwar
Journal:  J Virol Methods       Date:  2012-02-23       Impact factor: 2.014

2.  Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study.

Authors:  Adolf Pfefferbaum; David A Rogosa; Margaret J Rosenbloom; Weiwei Chu; Stephanie A Sassoon; Carol A Kemper; Stanley Deresinski; Torsten Rohlfing; Natalie M Zahr; Edith V Sullivan
Journal:  Neurobiol Aging       Date:  2014-01-13       Impact factor: 4.673

Review 3.  Neuroimaging of HIV-associated neurocognitive disorders (HAND).

Authors:  Beau M Ances; Dima A Hammoud
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

Review 4.  Role of neuroimaging in HIV-associated neurocognitive disorders.

Authors:  Mary C Masters; Beau M Ances
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

5.  Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-tailed macaques.

Authors:  Kelly A Metcalf Pate; Claire E Lyons; Jamie L Dorsey; Erin N Shirk; Suzanne E Queen; Robert J Adams; Lucio Gama; Craig N Morrell; Joseph L Mankowski
Journal:  J Infect Dis       Date:  2013-07-11       Impact factor: 5.226

6.  TGFβ-Mediated Downregulation of Thrombopoietin Is Associated With Platelet Decline in Asymptomatic SIV Infection.

Authors:  Kelly A Metcalf Pate; Claire E Lyons; Jamie L Dorsey; Suzanne E Queen; Robert J Adams; Craig N Morrell; Joseph L Mankowski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

7.  Platelet-endothelial associations may promote cytomegalovirus replication in the salivary gland in mice.

Authors:  Alicia M Braxton; Alyssa L Chalmin; Kevin M Najarro; Jacqueline K Brockhurst; Karl T Johnson; Claire E Lyons; Brenna Daly; Catherine G Cryer; Shefali Vijay; Griffin Cyphers; Selena M Guerrero-Martin; S Andrew Aston; Kirstin McGee; Yu-Pin Su; Ravit Arav-Boger; Kelly A Metcalf Pate
Journal:  Platelets       Date:  2019-11-14       Impact factor: 4.236

8.  Platelet Activation in Human Immunodeficiency Virus Type-1 Patients Is Not Altered with Cocaine Abuse.

Authors:  Michelle Kiebala; Meera V Singh; Michael S Piepenbrink; Xing Qiu; James J Kobie; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

9.  Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.

Authors:  Donna C Davidson; Giovanni Schifitto; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disorders.

Authors:  Donna C Davidson; Michael P Hirschman; Anita Sun; Meera V Singh; Karl Kasischke; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.